Novel Synergistic Protective Efficacy of Atovaquone and Diclazuril on Fetal-Maternal Toxoplasmosis
نویسندگان
چکیده
منابع مشابه
Novel Synergistic Protective Efficacy of Atovaquone and Diclazuril on Fetal-Maternal Toxoplasmosis.
Over 1 billion people globally are estimated to be infected with Toxoplasma gondii with severe or unknown consequences and no safe and effective therapies are available against congenital or persistent chronic infection. We propose that atovaquone and diclazuril synergistically protect against fetal-maternal toxoplasmosis. METHODS Programmed pregnant mice were treated with atovaquone and dicl...
متن کاملToxoplasmosis complications and novel therapeutic synergism combination of diclazuril plus atovaquone
UNLABELLED Toxoplasmosis is a major cause of foodborne disease, congenital complication, and morbidity. There is an urgent need for safe and effective therapies to encounter congenital and persisting toxoplasmosis. The hypothesis was: combination diclazuril plus atovaquone to exert a novel therapeutic synergy to prevent toxoplasmosis syndromes. METHODS Pregnant dams were treated with diclazur...
متن کاملDiclazuril Protects against Maternal Gastrointestinal Syndrome and Congenital Toxoplasmosis
BACKGROUND Toxoplasmosis is a common cause of foodborne, gastrointestinal and congenital syndrome with particularly severe or unknown health consequences. There is no safe and effective preventive or therapeutic modality against congenital toxoplasmosis or to eliminate the persistent chronic infection. HYPOTHESIS Diclazuril to be safe in pregnancy and effective against gastrointestinal toxopl...
متن کاملSynergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis.
The effect of clindamycin (CLI) combined with autovaquone (ATO) was examined in a murine model of acute toxoplasmosis. Swiss Webster mice intraperitoneally infected with 10(2) or 10(4) tachyzoites of the RH strain of Toxoplasma gondii were perorally treated with either drug alone (for ATO, 5, 25, 50, or 100 mg/kg of body weight/day; for CLI, 25, 50, or 400 mg/kg/day) or both combined (for ATO p...
متن کاملAtovaquone ameliorate gastrointestinal Toxoplasmosis complications in a pregnancy model
BACKGROUND Toxoplasma is an important source of foodborne hospitalization with no safe and effective therapy against chronic or congenital Toxopalsmosis. Atovaquone is a drug of choice but not approved for use in congenital Toxoplasmosis. We hypothesized atovaquone to be safe and effective against feto-maternal Toxoplasmosis. MATERIAL/METHODS Programmed pregnant mice were i.p. infected with 5...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Clinical Medicine
سال: 2014
ISSN: 2158-284X,2158-2882
DOI: 10.4236/ijcm.2014.515124